Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Both companies signed a commercial supply agreement, for a novel formulation of glycopyrrolate (Dartisla) using Catalent’s proprietary Zydis® orally disintegrating tablet delivery technology intended for use as adjunctive therapy in the treatment of patients with peptic ulcer.
Lead Product(s): Glycopyrronium Bromide
Therapeutic Area: Gastroenterology Product Name: Dartisla
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Catalent Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 10, 2021